PROGRAM MENU

EDUCATIONAL PROGRAM

WORKSHOPS & SYMPOSIA

CONTINUING EDUCATION


Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. The THSNA 2020 program will include on demand access to recorded talks covering four educational tracks as well as live panel discussion sessions, a nursing workshop, digital posters, corporate symposia, and a virtual exhibit hall with commercial booths.

Note that all timea are listed in Eastern Daylight Time (EDT) and any aspect of this program is subject to change.


Friday, October 30th

10:00 - 11:30 AM
PLENARY 4: WE’RE ALL IN THIS FIGHT TOGETHER: PERSPECTIVES ON COVID-19
Chair/Organizer: Anne Rose, Cathy Hayward, Robert Sidonio
Virtual Room 1

Over the past year, the world has battled the global pandemic caused by the virus COVID-19. Experts in this closing Plenary will cover broad and unique perspectives on COVID-19 infection and what has been learned from fighting this infection in North America and beyond. The session will also address some fascinating aspects of COVID-19, including how this infection can affect children and the importance of recognizing and addressing the thrombotic complications of COVID-19.


1
Overview of COVID-19: A broad perspective on what we've been through in North America and beyond
Zain Chagla. McMaster University

2
COVID-19 infection in children
Jennifer Davila. Children's Hospital at Montefiore

3
COVID-19 and Thrombosis
Rachel Rasovsky. Massachusetts General Hospital
12:15 - 1:15 PM
CORPORATE LUNCH SYMPOSIM: FINAL RESULTS FROM THE NUWIQ® PUP STUDY: INHIBITOR RATES & BEYOND
Virtual Room 1

Sponsored By: Octapharma

Dr. Ellis Neufeld will present final data from the NuProtect study. Octapharma USA is the sponsor of this program. NuProtect is a prospective, multinational, open-label, phase III study to assess the immunogenicity, efficacy and safety of NUWIQ® Antihemophilic Factor (Recombinant), a human cell line-derived rFVIII, in previously untreated patients (PUPs) with severe hemophilia A. NuProtect is the largest prospective study of a single FVIII product in PUPs with hemophilia A, conducted in 105 PUPs followed for up to 100 exposure days. Final results showed a cumulative incidence of high-titer inhibitors of 17.6%. Dr. Neufeld will discuss these results in the context of the SIPPET study, in which the cumulative incidence of high-titer inhibitors was 28.4% in patients treated with rFVIII products derived from hamster cell lines and 18.6% in those treated with plasma-derived FVIII. In addition, new data on efficacy and implications of FVIII gene mutation analysis will be shared. The completion of NuProtect represents a major clinical milestone for NUWIQ and the hemophilia community.


CORPORATE LUNCH SYMPOSIUM: INVESTIGATIONAL AAV GENE THERAPIES: PRACTICAL SITE CONSIDERATIONS (LIVE ONLY - NOT RECORDED)
Virtual Room 2

Sponsored By: BioMarin

Join us to understand what makes AAV gene therapy research and its potential practical applications different from other treatment types. Dr. Guy Young will discuss the technology behind the adeno-associated virus platform being investigated and also the important questions providers of myriad specialties and institutions may have as they prepare for what could be a very different journey from consideration and eligibility, to practice, to short and longer-term post-procedure follow-up. A live Q&A session with Dr. Guy Young will be held after to answer any questions.

2:00 - 3:30 PM
ADVANCES IN UNDERSTANDING BLEEDING DISORDERS
Chair/Organizer: Julie Jaffray, Roona Sinha
Virtual Room 2

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.


1
FVIII And Its Role As The Genetic Basis Of Hemophilia
Chris Doering.

2
Modeling Immune-Mediated Thrombocytopenia: Insights On Mechanisms
Heyu Ni. University of Toronto / Canadian Blood Services Centre for Innovation

3
Genotype/Phenotype Discrepancies In Rare Bleeding Disorders
Diane Nugent. CHOC Childrens Hospital/UC Irvine and Center for Inherited Blood Disorders
ANTICOAGULATION STEWARDSHIP
Chair/Organizer: Leslie Lake, Teresa Bordeaux
Virtual Room 3

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.


1
The Future Of Anticoagulation Clinics And Role Of Clinicians
Arthur Allen. VA Salt Lake City Health Care System

2
Establishing an Anticoagulation Stewardship Program (Review of FDA/TJC Standards And AC Forum Guidance)
Scott Kaatz. Henry Ford Hospital

3
Anticoagulation Stewardship Programs (Examples Of Excellence)
Anne Rose. UW Health
UPDATE ON LABORATORY TESTING FOR ACQUIRED DISORDERS
Chair/Organizer: Joyce Rogers, Dot Adcock
Virtual Room 1

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an “Ask a Question” option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.


1
Update On Testing For Autoantibodies In Acquired Hemophilia
Ken Friedman. Versiti - Bloodcenter of Wisconsin

2
Laboratory Evaluation Of Acquired Von Willebrand Disease
William Nichols. Mayo Clininc - Rochester, MN

3
Laboratory Approach To Monitoring Coagulation During Life Support
Oksana Volod . Cedars Sinai Medical Center